Firestone Karen 4

What Happened Karen Firestone, a director of Amylyx Pharmaceuticals, was granted a derivative award on June 4, 2026 covering 24,372 shares. The filing lists an acquisition price of $0.00 (i.e., no cash paid at grant). This is a grant/award (not a market purchase or sale) typically part of director compensation rather than an outright purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (filed within the standard two business days, appears timely).
• Award: derivative grant covering 24,372 shares; price listed $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: the shares subject to this option will vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to Ms. Firestone’s continuous service through the vesting date.
• Transaction code: A = Award/Grant (derivative). No tax-withholding, 10b5-1 plan, or cashless sale noted.

Context This is a routine director compensation award and does not represent an open-market purchase or sale by the insider. Such grants can dilute outstanding shares if exercised/settled in the future; the award here vests based on continued service and a time-based condition. As always, grants are informative about compensation but do not, by themselves, indicate the insider’s immediate market view.